We are live on ! Find out more
CORV

Correvio Pharma Corp. Ordinary Shares (Canada)
CORV

Delisted

CORV was delisted on the 26th of May, 2020.

39 hedge funds and large institutions have $49.2M invested in Correvio Pharma Corp. Ordinary Shares (Canada) in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

33% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 9

18% more capital invested

Capital invested by funds: $41.6M → $49.2M (+$7.52M)

8% more funds holding

Funds holding: 3639 (+3)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
39
Holders Change
+3
Holders Change %
+8.33%
% of All Funds
0.85%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
12
Reduced
9
Closed
3
Calls
$31K
Puts
Net Calls
+$31K
Net Calls Change
+$230K

CORV Hedge Fund Activity: Q3 2019 in Review

39 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) for Q3 2019, worth a combined $49.2M — up 18% from $41.6M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new CORV positions and 3 closed out — a net gain of 3 holders — while 12 added to existing stakes and 9 trimmed.

The largest buyer was Putnam Investments, adding an estimated $2.7M. The largest seller was Essex Investment Management, cutting an estimated $430K.

  • 39 institutional investors held Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) as of Q3 2019, up from 36 in Q2 2019.
  • Funds reported $49.2M of Correvio Pharma Corp. Ordinary Shares (Canada) stock for Q3 2019, up 18% quarter-over-quarter.
  • 6 funds opened new Correvio Pharma Corp. Ordinary Shares (Canada) positions in Q3 2019 and 3 closed out, a net change of +3 holders.
  • The largest Correvio Pharma Corp. Ordinary Shares (Canada) buyer in Q3 2019 was Putnam Investments, an estimated $2.7M added.
  • The largest Correvio Pharma Corp. Ordinary Shares (Canada) seller in Q3 2019 was Essex Investment Management, an estimated $430K sold.

Based on aggregated 13F filings for Q3 2019.